The Osteoporosis drugs in development market research report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Osteoporosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Osteoporosis and features dormant and discontinued products.

GlobalData tracks 181 drugs in development for Osteoporosis by 153 companies/universities/institutes. The top development phase for Osteoporosis is preclinical with 81 drugs in that stage. The Osteoporosis pipeline has 151 drugs in development by companies and 30 by universities/ institutes. Some of the companies in the Osteoporosis pipeline products market are: University of Wisconsin Madison, Omeros and University of Toledo.

The key targets in the Osteoporosis pipeline products market include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11), Parathyroid Hormone Receptor, and Sclerostin (SOST).

The key mechanisms of action in the Osteoporosis pipeline product include Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or RANKL or CD254 or TNFSF11) Inhibitor with 32 drugs in Pre-Registration. The Osteoporosis pipeline products include eight routes of administration with the top ROA being Subcutaneous and 13 key molecule types in the Osteoporosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Osteoporosis overview

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, and a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

For a complete picture of Osteoporosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.